Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

NCT05270057 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT05270057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05270057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Lead sponsor
Medical College of Wisconsin
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 26, 2023
Completion date
October 11, 2027
Enrollment
11 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, burkitt lymphoma